🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections per year. Especially elevated rates are observed in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in the same week. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

Based on data detailed in a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This establishes an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Doctors treating patients have voiced hope. Access to a one-pill regimen like this is hailed as a "revolutionary step" for public health efforts. This is deemed vital to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea globally.